摘要
近年来,嵌合抗原受体修饰T细胞(chimeric antigen receptor engineered T cell,CAR-T)免疫疗法发展迅速。CD19-CAR-T在复发难治性急性淋巴细胞白血病(relapsed refractory acute lymphocytic leukemia,RR-ALL)的治疗中取得满意疗效,但易复发。本文就CD19-CAR-T治疗RR-ALL后复发相关因素及应对策略的研究进展作一综述。
Chimeric antigen receptor engineered T cell （CAR T） develops very quickly. Immunotherapy with CD19 CAR-T has achieved a promising clinical result in the past few years, especially in the treatment of relapsed refractory acute lymphocytic leukemia （RR-ALL）. At present, the most serious challenge is the relapse of RR ALI. after CD19-CAR-T therapy. This paper reviews the research progress of the relapse related factors and strategies for RR-ALL treated with CD19-CAR-T.
作者
王海涛
李丽敏
付玥玥
周晋
WANG Hai tao, LI Li-min, FU Yue-yue, ZHOU Jin(Department of Hematology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, Chin)
出处
《中华实用诊断与治疗杂志》
2018年第3期301-303,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
国家自然科学基金(8143008)
